Navigation Links
CB1400, Patented by Canopus BioPharma, Prevents Tumor Growth and Enhances the Anti-Tumor Effects of Cisplatin and Cetuximab (Erbitux).
Date:6/19/2008

LOS ANGELES, California, June 19 /PRNewswire-FirstCall/ -- Canopus BioPharma, Inc. (OTC: CBIA), has confirmed the efficacy of its oncology candidate, CB1400, as a tumor reducing agent and has also demonstrated the synergistic effect of this drug in combination with both cisplatin and cetuximab (Erbitux) in two mice lung cancer models.

Chairman of Canopus BioPharma, Dr. Patrick Prendergast, stated, "We at Canopus are encouraged with the discovery of this new use for CB1400 to increase efficacy and reduce toxicity issues associated with conventional chemotherapeutic agents."

CB1400, a former schistosomal drug, is currently in phase II clinical development as an anti-mucositis preventative agent in patients receiving radio- and/or chemotherapy treatment. Current anti-mucositis drugs have shown tumor-protective properties. For this reason CB1400 was evaluated by Canopus to determine its effect on tumor growth.

In work carried out by the Harvard School of Dental Medicine, Boston, on behalf of Canopus BioPharma, it was confirmed that CB1400 as a single agent significantly reduces tumor growth. In an initial study, tumor growth was inhibited by 48.8% in mice treated with cisplatin, the most commonly used chemotherapy drug. CB1400 alone showed 62.3% tumor growth inhibition while the combination of both compounds further increased inhibition to 69.6%, thus confirming a synergistic effect between cisplatin and CB1400. In addition, there was no evidence of toxicity based on observations of survival and weight change in the mice and there was no evidence that CB1400 protected the tumor.

Cisplatin is a platinum-containing chemotherapeutic drug, administered by IV injection which has been used for more than 30 years to treat various forms of cancer. Enhanced efficacy with CB1400 may prevent the development of drug resistance that is common with cisplatin.

In a similar study, tumor growth was inhibited by 61% in mice treated with cetuximab
'/>"/>

SOURCE Canopus BioPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. China Biopharma, Inc. Announces New Plan of Operation
2. Flash Technology Prevents Pain From Carpal Tunnel Syndrome
3. InSightec Resumes Clinical Trials for Non-Invasive Treatment of Brain Tumors
4. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
5. First New Class of Platinum-Based Chemotherapy Drug Candidates in 30 Years Demonstrate Ability to Kill Tumors Resistant to Currently Marketed Platinum Drugs
6. New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties
7. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
8. Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio of Irinotecan and Cisplatin to Improve Anti-tumor Activity
9. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
10. On the road to a new cancer therapy -- starving the tumor
11. Virginia Commonwealth University to Study Genomics-Based Diagnostic Test: Pathwork Diagnostics Tissue of Origin Test Designed to Aid in Determination of a Tumors Origin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Calif. , July 29, 2014  ImmunoClin ... in personalized medicine, treatment of infectious diseases as ... of prognosis and prevention of pathologies like cardiovascular ... August 1, 2014, ImmunoClin Corporation will complete the ... Washington, D.C. , a key center ...
(Date:7/29/2014)... Tenn. (PRWEB) July 29, 2014 ... in biomass feedstock supply innovation and supply chain ... proprietary feedstock management systems, Energy Grange™ and Supply ... of R&D and in-the-field testing aimed at consolidating ... offering benefits to landowners, farmers and feedstock end ...
(Date:7/29/2014)... 2014  United Therapeutics Corporation (NASDAQ: ... results for the second quarter ended June 30, ... that our medicines are reaching increasing numbers ... (PAH)," said Martine Rothblatt, Ph.D., United Therapeutics, ... launch this quarter of our extended-release tablet ...
(Date:7/29/2014)... The prestigious "Discovery or Exploration in History Award" ... Juliana Hillis and Kaylie O’Connell, students at Stoneham High ... Egg, Everything: America’s First IVF Baby". This project was ... History Day program during a week-long final competition judged ... D.C. , The growing popularity of the assisted reproductive ...
Breaking Biology Technology:ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 2ImmunoClin Corporation (IMCL) Relocates Corporate Headquarters to Washington, DC 3Genera Energy Introduces Proprietary Feedstock Management Systems 2Genera Energy Introduces Proprietary Feedstock Management Systems 3Genera Energy Introduces Proprietary Feedstock Management Systems 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 11United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 12United Therapeutics Corporation Reports Second Quarter 2014 Financial Results 13In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 2In Vitro Fertilization (IVF) was the Subject of This Year’s Winning Entry for the Prestigious Library of Congress “Discovery or Exploration in History Award” 3
... CINCINNATI, June 16, 2011 Kendle (Nasdaq: ... research organization, today announced several of its senior ... issues at the Drug Information Association (DIA) 47th ... experts will address key topics, including the benefits ...
... , New Generation of the Ziehm Vision RFD ... Imaging has launched a new generation of the Ziehm Vision,RFD ... allows it to be used over an almost unlimited period,of ... ORs.,Thanks to its mobility and significantly lower investment costs,the Ziehm ...
... 2011 NewCardio, Inc., (OTC BB: NWCI) a ... of its recent medical and technical submissions have ... Annual International Conference of the IEEE Engineering in ... The two papers: ,Wireless Monitoring of Reconstructed 12-Lead ...
Cached Biology Technology:Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 2Kendle Experts to Address Key Industry Issues at Drug Information Association 47th Annual Meeting 3SVS 2011: Ziehm Imaging Presents Latest Mobile C-armTechnology for Intraoperative use 2NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 2NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 3NewCardio Selected to Present at 33rd Annual International Conference of the IEEE Engineering in Medicine and Biology Society 4
(Date:7/28/2014)... pinpointed a mechanism in part of the brain that is ... to both type 1 and type 2 diabetes. The findings ... of the National Academies of Sciences . , "We,ve ... part of the hypothalamus known as the ventromedial nucleus ... levels in the blood," said lead author Sabrina Diano, professor ...
(Date:7/28/2014)... The genome of Solanum pennellii , a wild ... an international group of researchers including the labs headed ... UC Davis Department of Plant Biology. The new genome ... , The work, published July 27 in the journal ... and colleagues at Aachen University in Germany. The UC ...
(Date:7/28/2014)... for Alzheimer,s disease and other forms of dementia, but ... treatment. , University of Washington bioengineers have a designed ... of the body,s normal proteins into a state that,s ... disease, Type 2 diabetes and Lou Gehrig,s disease. The ... their normal state into an abnormally folded form by ...
Breaking Biology News(10 mins):Glucose 'control switch' in the brain key to both types of diabetes 2New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3
... DigitalPersona, Inc., a leader in fingerprint identity ... Solutions Company is now offering U.are.U fingerprint sensors ... modular point-of-sale (POS) workstation, the Stingray JS-950. The ... can be attached to either side of the ...
... land degradation in dryland regions continuing to worsen, ... on scientist-recommended indicators for monitoring and assessing desertification ... landmark agreement was reached after two weeks of ... attending the Ninth Session of the Conference of ...
... Israel, October 7, 2009 H2 Blocker drugs, such as ... reflux (heartburn), pose no significant risks for the fetus according ... University of the Negev. The study published in the ... the safety of the fetus when H2 blocker drugs ...
Cached Biology News:Panasonic Offers U.are.U(R) Fingerprint Sensor From DigitalPersona on Stingray JS-950 Point-of-Sale Workstations 2Satellite data instrumental in combating desertification 2Satellite data instrumental in combating desertification 3Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers 2
Purified Mouse anti-Hu LAT (pY226) Storage Temperature: Refrigerate(2 to 8C)...
Tris-EDTA Buffer Solution, 1X, pH 8.0, sterile, Molecular Biology Grade...
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
...
Biology Products: